
Feature|Videos|July 14, 2025
Effective Tactics for Pricing and Reimbursement in Today’s Market
A panel of key opinion leaders consider how payers and manufacturers are increasingly embracing innovative contracting models that require strong value propositions, strategic planning, and significant upfront investment in data and stakeholder alignment.
Advertisement
Episodes in this series

In this episode, the panelists provide a candid look at how payers are increasingly open to innovative reimbursement structures—but only if the groundwork is thoughtfully laid. It’s not enough to pitch a novel payment model; manufacturers must bring solutions tied to the payer’s biggest challenges and be ready to share risk.
Key discussion topics include:
- Designing outcome-based contracts aligned with payer data systems.
- When and how to engage payer medical directors in model design.
- Differences in feasibility across pharmacy and medical benefit products.
- Why a strong value proposition must precede any innovative contract.
Advertisement
Related to this article

Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.

Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.

Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.

In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.

Accessia Health’s Tiara Green says Part D reforms eased drug costs, but premiums, deductibles and payer policies still limit patient access.

ELPRO CEO Frederik Dresen explains how cold chain monitoring moved from compliance to risk management, and what biologics and advanced therapies demand.

Inizio Ignite leaders argue static, milestone-driven launch plans fall short and AI sharpens execution only when built on a sound strategy.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: CVS Health to Break in Two, Bayer Weighs MFN
2
2026 Brought Progress on Drug Prices. What Will It Take to Improve Patient Access in 2027?
3
Big Three Distributors Lean on Specialty for Profit Growth
4
The System-Level View That Sound Market Access Decisions Are Missing
5

